Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHALIN vs DEL-VI-A
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.
Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.
Hypertension (FDA-approved),Attention deficit hyperactivity disorder (ADHD) (off-label),Opioid withdrawal (off-label)
Moderate to severe plaque psoriasis,Psoriatic arthritis,Crohn's disease
500 mg orally once daily
10 mg orally once daily, taken with or without food.
Terminal half-life 12-15 hours (healthy adults); prolonged to 24-30 hours in renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life is 12-15 hours in patients with normal renal function. Half-life is prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and requires dose adjustment.
Primarily hepatic via cytochrome P450 isoenzyme CYP2D6; metabolites are excreted renally.
Metabolized via catabolic pathways into small peptides and amino acids.
Renal excretion (70% unchanged); fecal/biliary (20%); metabolism (10%)
Renal excretion of unchanged drug accounts for 60-70% of elimination, with 20-30% excreted as glucuronide conjugate. Biliary/fecal excretion accounts for approximately 10%.
98% bound primarily to albumin
Approximately 85% bound to serum albumin.
0.3-0.5 L/kg; reflects limited extravascular distribution consistent with high protein binding
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in obesity (up to 1.2 L/kg) suggests extensive tissue binding.
Oral: 80-90% (first-pass metabolism ~10-20%); IM: 95-100%
Oral bioavailability is 60-70% due to first-pass metabolism. No significant food effect observed.
e GFR 30-59 m L/min: 250 mg orally once daily; e GFR 15-29 m L/min: 125 mg orally once daily; e GFR <15 m L/min: 125 mg orally every 48 hours
Cr Cl 30-89 m L/min: no adjustment; Cr Cl 15-29 m L/min: 5 mg once daily; Cr Cl <15 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 250 mg orally once daily; Child-Pugh Class C: 125 mg orally once daily
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
10-15 mg/kg orally once daily, not to exceed 500 mg/day
Not approved for patients <18 years. Safety and efficacy not established.
Initiate at 250 mg orally once daily; titrate based on renal function
No specific dose adjustment; use caution due to age-related renal impairment and potential for orthostatic hypotension.
Avoid abrupt discontinuation; rapid withdrawal can cause rebound hypertension, anxiety, and, in severe cases, hypertensive encephalopathy or stroke.
None.
May cause sedation, dizziness, and orthostatic hypotension. Use caution in patients with cerebrovascular or cardiovascular disease. Monitor blood pressure regularly. Do not administer with other alpha-2 agonists.
Increased risk of infections including tuberculosis,Hypersensitivity reactions,Hepatic transaminase elevations
Hypersensitivity to ALPHALIN or any component; concurrent use with other alpha-2 adrenergic receptor agonists; severe bradycardia or heart block (unless paced).
Known hypersensitivity to delvi-ā or any excipients,Active serious infections
No specific food interactions documented. However, avoid alcohol for 24 hours post-administration due to additive hypotensive effects. Grapefruit juice may potentiate alpha-blocker effects; avoid concurrent use.
Take with meals to reduce gastrointestinal side effects. Avoid high-fat meals as they may decrease delavirdine absorption. Grapefruit juice may increase delavirdine levels; avoid concurrent use. No other significant food interactions known.
First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.
DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Second and third trimester exposure linked to fetal growth restriction and oligohydramnios.
Contraindicated during breastfeeding due to high transfer into breast milk; M/P ratio > 1.5.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended. M/P ratio not available.
Dose reduction by 30-50% recommended in second and third trimesters due to increased clearance.
No safe dose established; drug is contraindicated in pregnancy. Due to altered pharmacokinetics (increased volume of distribution, enhanced clearance), if inadvertent exposure occurs, no dose adjustment can be recommended as any exposure poses fetal risk.
ALPHALIN is a high-potency alpha-blocker indicated for hypertensive emergencies. Administer as a slow IV bolus over 5 minutes to avoid severe hypotension. Monitor blood pressure every 2 minutes during infusion. Have intravenous fluids and vasopressors ready. Contraindicated in patients with known hypersensitivity, acute myocardial infarction, or history of orthostatic hypotension.
DEL-VI-A is a combination of delavirdine and vitamin A. Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1. Monitor for hepatotoxicity, especially in patients with hepatitis B/C coinfection or pre-existing liver disease. Administer with food to reduce GI upset. Vitamin A component may cause hypervitaminosis A if taken with other supplements. Use with caution in patients with renal impairment; no dose adjustment needed for mild-moderate, but avoid in severe (Cr Cl <30 m L/min).
This medication is given intravenously in a hospital setting only.,You will have continuous blood pressure monitoring during administration.,Report any dizziness, chest pain, or difficulty breathing immediately.,After treatment, rise slowly from sitting or lying to prevent fainting.,Avoid alcohol for 24 hours after treatment to prevent blood pressure drop.
Take DEL-VI-A exactly as prescribed, typically three times daily with food.,Do not skip doses or stop taking without consulting your doctor, as this may lead to drug resistance.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, pale stools, or persistent nausea.,Avoid taking additional vitamin A supplements or multivitamins containing vitamin A to prevent toxicity.,DEL-VI-A does not cure HIV or prevent transmission; continue safe sex practices.
No interactions on record
No interactions on record
Common clinical questions about ALPHALIN vs DEL-VI-A, answered by our medical review team.
ALPHALIN is a Vitamin A Supplement that works by ALPHALIN is an alpha-2 adrenergic receptor agonist that decreases sympathetic outflow from the central nervous system, resulting in reduced peripheral vascular resistance, decreased heart rate, and lowered blood pressure.. DEL-VI-A is a Vitamin A supplement that works by Delvi-ā is a monoclonal antibody that binds to the interleukin-23 (IL-23) p19 subunit, inhibiting IL-23-mediated signaling and reducing inflammatory cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHALIN and DEL-VI-A depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHALIN is: 500 mg orally once daily. The standard adult dose of DEL-VI-A is: 10 mg orally once daily, taken with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHALIN and DEL-VI-A in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHALIN is classified as Category C. First trimester: Increased risk of neural tube defects and cardiovascular malformations; second and third trimesters: Risk of fetal growth restriction and oligohydramnios.. DEL-VI-A is classified as Category C. DEL-VI-A is contraindicated in all trimesters due to documented teratogenicity. First trimester exposure associated with neural tube defects and cardiovascular malformations. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.